Understanding the Allegations Against ADMA Biologics: Investor Insights and Implications

Investor Alert: Unpacking the Allegations Against ADMA Biologics

Pomerantz LLP, a prominent law firm recognized for its expertise in corporate and securities class action litigation, has launched an investigation into claims from investors of ADMA Biologics, Inc. The focus is on whether the company and its executives have been involved in securities fraud or other questionable business activities.

ADMA Biologics operates in the biopharmaceutical sector, specializing in immunoglobulin products derived from human plasma. On March 24, 2026, an important development occurred when Culper Research released a report that raised serious allegations against ADMA. The report suggested that the company’s reported sales growth was significantly overstated and largely fabricated through unethical practices, notably described as a "channel stuffing scheme."

Channel stuffing refers to a practice where a company sends more products to distributors than they can sell to inflate sales figures. According to the report, without this allegedly misleading practice, ADMA's revenue actually decreased by 3% in 2025, contrasting sharply with the reported 20% growth. This revelation triggered a sharp decline in ADMA's stock price, which plummeted by 16.63% on the day the report was published.

Further compounding the situation, on March 26, 2026, Cantor Fitzgerald downgraded ADMA's stock rating, citing dissatisfaction with the company's inadequate response to the allegations presented in the Culper report. Investors reacted negatively, leading to another drop of 13.91% in the stock price, closing at $8.29 per share.

ADMA’s challenges continued as the firm announced on May 6, 2026, the withdrawal of its long-term financial guidance. This decision was attributed to changing competitive dynamics in the U.S. plasma products and immunoglobulin markets and contributed to an additional decline in stock price, which ultimately fell to $8.47 per share by May 7, 2026.

In the landscape of securities litigation, Pomerantz LLP has established a strong reputation, having recovered significant damages for clients in numerous class action lawsuits. Founded by Abraham L. Pomerantz, known for pioneering securities class actions, the firm continues to uphold this legacy by advocating for the rights of those affected by corporate misconduct and fraud.

As the investigation unfolds, investors who believe they have suffered losses due to ADMA's potentially deceptive practices are encouraged to reach out to Pomerantz LLP for guidance. The firm is committed to scrutinizing the evidence and ensuring that accountability is enforced in cases of securities fraud.

In conclusion, the allegations surrounding ADMA Biologics underline the importance of transparency and integrity in the corporate sector, particularly in industries impacting public health. Investors must remain vigilant and proactive in safeguarding their interests amid such allegations of misconduct. The legal steps taken by firms like Pomerantz LLP signify a critical check against corporate malpractice, reinforcing investor confidence in the regulatory framework designed to protect them.

For further inquiries, investors can contact Danielle Peyton at Pomerantz LLP at [email protected] or call 646-581-9980, ext. 7980. As this situation continues to develop, it will serve as a vital case study in the accountability of publicly traded companies and the role of law firms in pursuing justice for affected stakeholders.